Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rougier, P.
Right arrow Articles by Mitry, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rougier, P.
Right arrow Articles by Mitry, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:ii3-ii5, 2003
© 2003 European Society for Medical Oncology

Epidemiology, treatment and chemoprevention in colorectal cancer

P. Rougier+ and E. Mitry

Hospital Ambroise Paré, Boulogne Billancourt, France

Abstract

In Western countries, colorectal cancer (CRC) is second only to cancer of the lung as a cause of death from malignancy, and affects perhaps one in 20 of the population. In the pre-chemotherapy era, advances in surgery and earlier presentation led to some improvement in survival. However, no more than 60% of CRC patients can expect to be alive at 5 years. Adjuvant chemotherapy in stage III disease is of proven benefit. In metastatic CRC, chemotherapy extends disease-free and overall survival compared with best supportive care alone, and improves quality of life. In palliation, infusional 5-fluorouracil (5-FU) is more active than bolus regimens and is less toxic. Several new cytotoxic agents show promise in CRC. Notable among them is irinotecan, which extends survival both when used as a single agent second-line versus best supportive care alone, and when added to 5-FU/folinic acid in the first-line setting. Much CRC is familial, raising the prospect of targeted screening to aid early detection. Since the molecular events leading to CRC have become better characterized, there is also the possibility of developing chemoprotective agents.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.